Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Variants of the ADRB2 Gene in COPD: Systematic Review and Meta-Analyses of Disease Risk and Treatment Response

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Association Between Chronic Obstructive Pulmonary Disease and Type 2 Diabetes: A Systematic Review and Meta-Analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Analysis of FEV1 decline in relatively healthy heavy smokers: implications of expressing changes in FEV1 in relative terms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Economic and Health Consequences of COPD Patients and Their Spouses in Denmark-1998-2010

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Alzheimer's disease related biomarkers in bipolar disorder - A longitudinal one-year case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Physical exercise may increase plasma concentration of high-density lipoprotein-cholesterol in patients with alzheimer's disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The β2-adrenergic receptor (ADRB2) is an important regulator of airway smooth muscle tone in chronic obstructive pulmonary disease (COPD). Variants that impair ADRB2 function could increase disease risk or reduce the response to endogenous and inhaled adrenergic agonists in COPD. We performed a systematic review and three meta-analyses to assess whether three functional variants (Thr164Ile, Arg16Gly, and Gln27Glu) in the ADRB2 gene are associated with elevated risk of disease or reduced therapeutic response to inhaled β2-agonists in COPD. We searched the medical literature from 1966 to 2017 and found 16 relevant studies comprising 85381 study subjects. The meta-analyses found no significant association between ADRB2 genotype and COPD risk. The summary odds ratios (ORs) for COPD in Thr164Ile homozygotes and heterozygotes were 2.57 (95% confidence interval (CI): 0.54-12.4) and 1.17 (95% CI: 0.96-1.44), respectively. Corresponding summary ORs for COPD in Arg16Gly homozygotes and heterozygotes were 0.97 (95% CI: 0.76-1.22) and 1.01 (95% CI: 0.81-1.26), while summary ORs for COPD in Gln27Glu homozygotes and heterozygotes were 1.00 (95% CI: 0.80-1.25) and 0.94 (95% CI: 0.69-1.24), respectively. When stratified by ethnicity, the summary ORs for COPD did not differ from 1.0 for any of the ADRB2 variants among Asian, Caucasian, or African populations. We found no consistent associations between ADRB2 genotype and treatment response to inhaled β2-agonists in COPD. This systematic review and meta-analyses found that COPD risk and response to inhaled β2-agonists were not associated with Thr164Ile, Arg16Gly, and Gln27Glu genotypes. However, identified cases of Thr164Ile were few, and additional studies of rare ADRB2 genotypes are required.

OriginalsprogEngelsk
TidsskriftCOPD
Vol/bind14
Udgave nummer4
Sider (fra-til)451-460
Antal sider10
ISSN1541-2555
DOI
StatusUdgivet - aug. 2017

ID: 56121378